You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The offering consists of 2 million common shares offered by the company and 1.5 million common shares offered by selling shareholders at a price of $14 per share.
The Rostock, Germany-based company reported €12.1 million ($13.6 million) in revenues, missing the average analyst estimate of $14.7 million.
The company, headquartered in Rostock, Germany, reported €15.2 million ($16.4 million) in revenues for Q4, with growth driven by its pharmaceutical business.
Invitae will provide free genetic testing on a 53-gene panel and counseling to patients suspected of having an LSD to facilitate earlier diagnosis and appropriate treatment.
The insurer will cover testing at the Rady Children's Institute for Genomic Medicine for children in intensive care with unexplained medical conditions.
Public Health England will use the company's Victor EnLite instrument and EnLite Neonatal TREC kit at three of six sites to evaluate screening newborns for "Bubble Boy" disease.
Aiming to improve patient access to critical drugs and tests, a group of legislators have started a caucus to shore up bipartisan support for personalized medicine.
Blueprint provides 3,900 targeted single-gene and more than 200 panel tests covering 14 medical specialties, leveraging NGS and bioinformatics methods.
The deal provides whole-genome sequencing for patients with rare diseases or cancer and could make sequencing part of the standard of care for NHS England.
The legislation is intended to allow states to conduct whole-genome sequencing on children on Medicaid who have a disease with a suspected genetic cause.